The Functions of Cytochrome P450 ω-hydroxylases and the Associated Eicosanoids in Inflammation-Related Diseases
Open Access
- 14 September 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
Abstract
The cytochrome P450 (CYP) ω-hydroxylases are a subfamily of CYP enzymes. While CYPs are the main metabolic enzymes that mediate the oxidation reactions of many endogenous and exogenous compounds in the human body, CYP ω-hydroxylases mediate the metabolism of multiple fatty acids and their metabolites via the addition of a hydroxyl group to the ω- or (ω-1)-C atom of the substrates. The substrates of CYP ω-hydroxylases include but not limited to arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, epoxyeicosatrienoic acids, leukotrienes, and prostaglandins. The CYP ω-hydroxylases-mediated metabolites, such as 20-hyroxyleicosatrienoic acid (20-HETE), 19-HETE, 20-hydroxyl leukotriene B4 (20-OH-LTB4), and many ω-hydroxylated prostaglandins, have pleiotropic effects in inflammation and many inflammation-associated diseases. Here we reviewed the classification, tissue distribution of CYP ω-hydroxylases and the role of their hydroxylated metabolites in inflammation-associated diseases. We described up-regulation of CYP ω-hydroxylases may be a pathogenic mechanism of many inflammation-associated diseases and thus CYP ω-hydroxylases may be a therapeutic target for these diseases. CYP ω-hydroxylases-mediated eicosanods play important roles in inflammation as pro-inflammatory or anti-inflammatory mediators, participating in the process stimulated by cytokines and/or the process stimulating the production of multiple cytokines. However, most previous studies focused on 20-HETE,and further studies are needed for the function and mechanisms of other CYP ω-hydroxylases-mediated eicosanoids. We believe that our studies of CYP ω-hydroxylases and their associated eicosanoids will advance the translational and clinal use of CYP ω-hydroxylases inhibitors and activators in many diseases.This publication has 130 references indexed in Scilit:
- 5-Aminoimidazole-4-carboxyamide-ribonucleoside (AICAR)-Stimulated Hepatic Expression ofCyp4a10,Cyp4a14,Cyp4a31, and Other Peroxisome Proliferator-Activated Receptor α-Responsive Mouse Genes Is AICAR 5′-Monophosphate-Dependent and AMP-Activated Protein Kinase-IndependentThe Journal of pharmacology and experimental therapeutics, 2011
- Genistein, Resveratrol, and 5-Aminoimidazole-4-carboxamide-1-β-d-ribofuranoside Induce Cytochrome P450 4F2 Expression through an AMP-Activated Protein Kinase-Dependent PathwayThe Journal of pharmacology and experimental therapeutics, 2011
- Cytochrome P450 ω-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancerCancer Chemotherapy and Pharmacology, 2010
- 20-Hydroxy-5,8,11,14-eicosatetraenoic Acid Mediates Endothelial Dysfunction via IκB Kinase-Dependent Endothelial Nitric-Oxide Synthase UncouplingThe Journal of pharmacology and experimental therapeutics, 2009
- Protective effect of 20-HETE analogues in experimental renal ischemia reperfusion injuryKidney International, 2009
- Identification of pregnane-X receptor target genes and coactivator and corepressor binding to promoter elements in human hepatocytesNucleic Acids Research, 2009
- CYP4Fs Expression in Rat Brain Correlates with Changes in LTB4Levels after Traumatic Brain InjuryJournal of Neurotrauma, 2008
- Expression of CYP4F2 in human liver and kidney: Assessment using targeted peptide antibodiesArchives of Biochemistry and Biophysics, 2008
- Catalytic characterization and cytokine mediated regulation of cytochrome P450 4Fs in rat hepatocytesArchives of Biochemistry and Biophysics, 2007
- Resolution of in flammation: state of the art, definitions and termsThe FASEB Journal, 2007